Patents by Inventor Dar HEINZE

Dar HEINZE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION
    Publication number: 20240132853
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: August 25, 2023
    Publication date: April 25, 2024
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE
  • Human iPSC-based derivation of NK and T-cells using early Notch induction
    Patent number: 11788065
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: October 17, 2023
    Assignee: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo Mostoslavsky, Dar Heinze
  • HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION
    Publication number: 20210207100
    Abstract: The technology described herein relates to compositions and methods for the generation of a primordial NK/T cell, where the produced NK/T primordial cell can subsequently differentiate into T cells or NK cells at an extremely high efficiency and reproducibility. Other aspects relate to genetically modified iPSC cell lines, and method of their use to generate iPSC-derived NK/T primordial cells with a very high yield and high efficiency.
    Type: Application
    Filed: December 23, 2020
    Publication date: July 8, 2021
    Applicant: BOSTON MEDICAL CENTER CORPORATION
    Inventors: Gustavo MOSTOSLAVSKY, Dar HEINZE